Holen Sie sich die Stockscreener-App
205.46
1.65%
-3.3837
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ABBV?
Forum
Prognose
Dividendenhistorie
Schlusskurs vom Vortag:
$208.84
Offen:
$207.04
24-Stunden-Volumen:
1.79M
Relative Volume:
0.25
Marktkapitalisierung:
$363.30B
Einnahmen:
$61.16B
Nettoeinkommen (Verlust:
$4.19B
KGV:
87.01
EPS:
2.3614
Netto-Cashflow:
$17.82B
1W Leistung:
-3.63%
1M Leistung:
-10.74%
6M Leistung:
-10.77%
1J Leistung:
+9.86%
1-Tages-Spanne:
$205.38
$209.00
1-Wochen-Bereich:
$205.40
$220.45
52-Wochen-Spanne:
$164.39
$244.81
Abbvie Inc Stock (ABBV) Company Profile
Firmenname
Abbvie Inc
Sektor
Telefon
(847) 932-7900
Adresse
1 NORTH WAUKEGAN ROAD, NORTH CHICAGO, IL
Compare ABBV vs LLY, JNJ, AZN, MRK
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ABBV
Abbvie Inc
|
205.40 | 369.39B | 61.16B | 4.19B | 17.82B | 2.3614 |
LLY
Lilly Eli Co
|
920.99 | 835.81B | 65.18B | 20.64B | 5.96B | 22.59 |
JNJ
Johnson Johnson
|
240.84 | 585.39B | 94.19B | 26.80B | 19.70B | 11.05 |
AZN
Astrazeneca Plc
|
203.53 | 315.58B | 58.80B | 10.24B | 8.98B | 3.2788 |
MRK
Merck Co Inc
|
120.32 | 298.84B | 64.93B | 18.26B | 12.36B | 7.2751 |
Abbvie Inc Stock (ABBV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2026-02-20 | Eingeleitet | Barclays | Overweight |
| 2026-01-08 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2026-01-07 | Fortgesetzt | UBS | Neutral |
| 2025-12-10 | Hochstufung | HSBC Securities | Hold → Buy |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-11-04 | Herabstufung | DZ Bank | Buy → Hold |
| 2025-10-14 | Herabstufung | Erste Group | Buy → Hold |
| 2025-10-01 | Herabstufung | HSBC Securities | Buy → Hold |
| 2025-09-17 | Hochstufung | Berenberg | Hold → Buy |
| 2025-08-12 | Fortgesetzt | Piper Sandler | Overweight |
| 2025-08-07 | Hochstufung | Daiwa Securities | Neutral → Outperform |
| 2025-05-14 | Herabstufung | Citigroup | Buy → Neutral |
| 2025-04-22 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Fortgesetzt | BofA Securities | Neutral |
| 2024-12-05 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2024-11-22 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Outperform |
| 2024-11-04 | Hochstufung | Argus | Hold → Buy |
| 2024-10-17 | Eingeleitet | Bernstein | Mkt Perform |
| 2024-06-05 | Hochstufung | HSBC Securities | Hold → Buy |
| 2024-05-17 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-01-29 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-12-18 | Herabstufung | HSBC Securities | Buy → Hold |
| 2023-12-11 | Hochstufung | Goldman | Neutral → Buy |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-10-30 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-10-20 | Fortgesetzt | UBS | Neutral |
| 2023-09-29 | Eingeleitet | Raymond James | Outperform |
| 2023-07-25 | Eingeleitet | William Blair | Mkt Perform |
| 2023-07-14 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-05 | Herabstufung | Argus | Buy → Hold |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-22 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2023-02-10 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2022-11-18 | Eingeleitet | Credit Suisse | Outperform |
| 2022-11-08 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-08-01 | Herabstufung | Atlantic Equities | Overweight → Neutral |
| 2022-05-23 | Eingeleitet | SVB Leerink | Underperform |
| 2022-05-06 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2022-04-06 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-02-28 | Herabstufung | UBS | Buy → Neutral |
| 2022-02-03 | Bestätigt | BMO Capital Markets | Outperform |
| 2022-02-03 | Bestätigt | Barclays | Equal Weight |
| 2022-02-03 | Bestätigt | BofA Securities | Neutral |
| 2022-02-03 | Bestätigt | Goldman | Neutral |
| 2022-01-13 | Eingeleitet | Redburn | Buy |
| 2022-01-12 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Overweight |
| 2021-11-23 | Hochstufung | Societe Generale | Hold → Buy |
| 2021-07-27 | Fortgesetzt | Truist | Buy |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2020-11-10 | Fortgesetzt | Bernstein | Outperform |
| 2020-09-29 | Eingeleitet | Berenberg | Hold |
| 2020-06-23 | Hochstufung | Atlantic Equities | Neutral → Overweight |
| 2020-06-09 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2020-06-02 | Hochstufung | Argus | Hold → Buy |
| 2020-05-18 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-05-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-05-11 | Fortgesetzt | Morgan Stanley | Overweight |
| 2020-04-20 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-03-23 | Herabstufung | Societe Generale | Buy → Hold |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-06 | Eingeleitet | Mizuho | Buy |
| 2020-01-07 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2019-12-26 | Bestätigt | Cowen | Outperform |
| 2019-09-26 | Hochstufung | Citigroup | Neutral → Buy |
| 2019-08-20 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2019-06-27 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-06-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-05-28 | Eingeleitet | Goldman | Neutral |
| 2019-04-29 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
Alle ansehen
Abbvie Inc Aktie (ABBV) Neueste Nachrichten
Scotiabank Maintains AbbVie(ABBV.US) With Buy Rating, Maintains Target Price $280 - Moomoo
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales? - TradingView
AbbVie Lowers 2026 Earnings Guidance Amid Expenses - Intellectia AI
Sowell Financial Services LLC Has $10.85 Million Position in AbbVie Inc. $ABBV - MarketBeat
AbbVie forecasts $744M hit from drug pipeline costs - Crain's Chicago Business
The Best Dividend ETF to Buy in April 2026 If You Want Passive Income - The Motley Fool
AbbVie Inc. $ABBV Shares Purchased by Kelleher Financial Advisors - MarketBeat
AbbVie Inc. $ABBV Shares Purchased by JB Capital LLC - MarketBeat
Savvy Advisors Inc. Buys 6,646 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) stock price, news, quote and history - Yahoo Finance Singapore
AbbVie Inc. $ABBV is Advocate Group LLC's 4th Largest Position - MarketBeat
AbbVie's Financial Outlook Revised Amid Pipeline Progress and One-Time Charge - AD HOC NEWS
AbbVie Updates 2026 Adjusted EPS Guidance to $13.96–$14.16 Including Q1 Acquired IPR&D and Milestones Expense 1 - Minichart
AbbVie Inc. $ABBV Shares Bought by SteelPeak Wealth LLC - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Acquires 6,946 Shares of AbbVie Inc. $ABBV - MarketBeat
C2P Capital Advisory Group Trims AbbVie Stake - National Today
C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors Sells 8,610 Shares of AbbVie Inc. $ABBV - MarketBeat
AbbVie Inc. (ABBV) latest stock news and headlines - Yahoo Finance Australia
AbbVie reports $744 million IPR&D expense for Q1, updates 2026 earnings guidance - Investing.com
AbbVie & Amgen: Safe Dividend Stocks for Recession Fears | 2026News and Statistics - indexbox.io
Open Angle Glaucoma Market: Expanding Revenue Landscape to 2034 – DelveInsight | Visiox Pharma, TearClear, VivaVision Biotech, Abbvie, Ocuphire Pharma, Qlaris Bio, Nicox Ophthalmics, Sun Pharma - barchart.com
AbbVie Posts Record $61B Revenue as Skyrizi and Rinvoq Surge Past Peak Humira Sales - TIKR.com
Potential US Drug Tariffs Test AbbVie Margins And Growth Narrative - Yahoo Finance
AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know - Yahoo Finance
Global pharma companies that have publicly announced Trump drug pricing agreements - Reuters
AbbVie Inc Stock (ABBV) Moved Down by 3.20% on Apr 2: A Full Analysis - tradingkey.com
AbbVie stock price forecast: Downside risk builds as ABBV drops 3.07% to $208 - Traders Union
AbbVie Inc. $ABBV Shares Sold by Trust Co. of Vermont - MarketBeat
Assessing AbbVie (ABBV) Valuation After New Dermatology Data And FDA Label Update - Yahoo Finance
Compagnie Lombard Odier SCmA Raises Holdings in AbbVie Inc. $ABBV - MarketBeat
Banque Pictet & Cie SA Has $88.87 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
What You Need to Know Ahead of AbbVie’s Earnings Release - Barchart
AbbVie Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Thrivent Moderate Allocation Fund's AbbVie Inc(ABBV) Holding History - gurufocus.com
AbbVie Inc. $ABBV Stock Holdings Trimmed by Vaughan Nelson Investment Management L.P. - MarketBeat
Nisa Investment Advisors LLC Has $156 Million Stock Position in AbbVie Inc. $ABBV - MarketBeat
Moody Lynn & Lieberson LLC Has $43.98 Million Holdings in AbbVie Inc. $ABBV - MarketBeat
Meyer Handelman Co. Boosts Stock Holdings in AbbVie Inc. $ABBV - MarketBeat
Sarcopenia Treatments Market Is Going to Boom | AbbVie • Amgen • Pfizer • Novartis - openPR.com
AbbVie Inc. $ABBV Shares Bought by Capital Advisors Inc. OK - MarketBeat
AbbVie Inc. $ABBV Shares Sold by Allspring Global Investments Holdings LLC - MarketBeat
AbbVie (NYSE:ABBV) Shares Up 2%Time to Buy? - MarketBeat
AbbVie Inc. stock rises Tuesday, still underperforms market - MarketWatch
Pfizer, Bain Must Litigate Cerevel Investors’ AbbVie Deal Suit - Bloomberg Law News
ABBV Stock Quote Price and Forecast - CNN
Bernstein Maintains AbbVie(ABBV.US) With Hold Rating, Maintains Target Price $225 - 富途牛牛
AbbVie Inc Stock (ABBV) Moved Up by 3.26% on Mar 31: Drivers Behind the Movement - TradingKey
/C O R R E C T I O N -- AbbVie/ - Investing News Network
Will AbbVie's Oncology Drugs Aid Top Line in 2026? - The Globe and Mail
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting - Investing News Network
Allergan Aesthetics Announces Fourth Annual, All-Access CoolMonth with Deals on CoolSculpting® - AbbVie News Center
Finanzdaten der Abbvie Inc-Aktie (ABBV)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.08%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):